Mydayis

Brand name: Mydayis
Generic name: mixed salts of a single-entity amphetamine products
Schedule: 2
FDA approved use: central nervous system stimulant for the treatment of ADHD
Limitations: Children 12 years and younger, patients using MAOis or 14 days within the use of the last dose of MAOi
Dosage forms: ER capsules
Strengths: 12.5 mg, 25 mg, 37.5 mg, 50 mg
Starting dose: 12.5 mg once daily and increase by 12.5 mg per WEEK (max dose that's been studied is 25 mg, so that's the recommended max dose)
Adverse Reaction: Drug dependence, hypersensitivity to amphetamine products, hypertensive crisis if using Mydayis with MAOi, serious CV reactions, long-term suppression of growth, peripheral vasculopathy, seizures, serotonin syndrome (some others are mentioned below)
MOA: non-catecholamine sympathomimetic amines (mode of action in ADHD is unknown)
Pharmacodynamics: block the reuptake of norepinephrine and dopamine into presynaptic neuron and increase the release of these monoamines into etraneuronal space.

Be careful in starting this with patients who have cardiac disease.  There is a possibility for insomnia, so warn patients about this possibility.

Agents that acidify the stomach will decrease the blood levels of Mydayis while agents who alkalizes the stomach will increase the blood levels of Mydayis.

Mydayis can cause an increase in blood pressure and heart rate.  This medication might cause psychosis episodes or manic symptoms, so please monitor patients. 

They are unsure of the pregnancy risk of this medication and increase contractions to cause premature labor.  Not much knowledge is on elderly patient.  If patients have an impaired renal function, the dose should be decreased.

What the capsules look like?
12.5 mg


25 mg

37.5 mg

50 mg


For more info, the website and the package insert have been attached at the bottom.


Source
Official Website
package insert